ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

COVID-19 Risks & Treatment for Patients with Rheumatic Disease

Thomas R. Collins  |  December 4, 2020

The Global Rheumatology Alliance is an important tool for assessing COVID-19 risk, & the ACR COVID-19 Task Force provides treatment guidance to rheumatology practitioners.

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2020COVID-19COVID-19 Global Rheumatology AllianceGlobal Rheumatology Alliance

2020 Pediatric Rheumatology Research in Review

Carina Stanton  |  November 24, 2020

ACR CONVERGENCE 2020—This has been a busy year for research publications covering a number of pediatric rheumatic diseases, including the emerging multi-system inflammatory syndrome (MIS-C) associated with SARS CoV-2. Despite the many challenges brought about by the COVID-19 pandemic, a healthy collection of publications covering a wide range of pediatric rheumatology research topics were published…

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic ConditionsPediatric ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:COVID-19geneticshealth disparitiesJuvenile Arthritis (JIA)Kawasaki diseaseMultisystem Inflammatory Syndrome in Children (MIS-C)Pediatric Rheum

Experts Discuss Unique Challenges Posed by Difficult-to-Treat RA

Vanessa Caceres  |  November 24, 2020

ACR CONVERGENCE 2020—Patients with rheumatoid arthritis (RA) and concurrent liver disease or interstitial lung disease (ILD), or with treatment-refractory RA, pose treatment challenges, said panelists in the ACR Convergence 2020 session, How I Treat Difficult RA. Each panelist discussed a difficult case and raised big-picture questions on how to best treat patients facing each challenge….

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2020ACR Convergence 2020 – RA

Dr. Blair Solow’s Picks for the Top RA Research Presented at ACR Convergence 2020

Elizabeth (Blair) Solow, MD  |  November 23, 2020

ACR CONVERGENCE 2020—Held Nov. 5–9, the ACR’s first fully virtual annual meeting provided participants with a vast repository of new research related to rheumatoid arthritis (RA). To help you sort through the noise, Elizabeth (Blair) Solow, MD, an assistant professor of medicine in the Division of Rheumatic Diseases at UT Southwestern Medical Center, Dallas, offered …

Filed under:ACR ConvergenceConditionsMeeting ReportsResearch RheumRheumatoid Arthritis Tagged with:ACR Convergence 2020ACR Convergence 2020 – RABlair SolowElizabeth SolowHCQHYDROXYCHLOROQUINEHydroxychloroquine (HCQ)

ACR Introduces Draft Guideline for RA Management

Jason Liebowitz, MD, FACR  |  November 23, 2020

Treating RA can be complicated, especially if the patient is suffering from comorbidities. In a session at ACR Convergence 2020, experts discussed the development of a new ACR draft guideline for RA management & how it can be applied in real-life clinical practice.

Filed under:ACR ConvergenceClinical Criteria/GuidelinesConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2020ACR Convergence 2020 – RA

Dr. Ethan Craig Picks His Favorite Gout Abstracts from ACR Convergence 2020

Keri Losavio  |  November 19, 2020

In light of the release of the ACR’s new gout guideline, it’s not surprising that 50 abstracts of studies on various aspects of gout were accepted at ACR Convergence 2020. Here, we highlight just a few:

Filed under:ACR ConvergenceConditionsGout and Crystalline ArthritisMeeting Reports Tagged with:ACR Convergence 2020ACR Convergence 2020 – GoutGoutpegloticaseserum uric acid

Chikungunya Virus May Lead to Long-Term Joint Pain

Linda Childers  |  November 18, 2020

COVID-19 isn’t the only viral infection on the rise across the globe, so is chikungunya, which can cause arthritis-like symptoms and may lead to long-term joint pain.

Filed under:ConditionsPain Syndromes Tagged with:arthritis painchikungunyaCHIKVChronic painJoint Pain

Upadacitinib Safety Similar to Other Jakinibs for RA

Lisa Rapaport  |  November 16, 2020

(Reuters Health)—A once-daily 15 mg dose of upadacitinib for rheumatoid arthritis (RA) has similar rates of malignancies, serious infections, major adverse cardiovascular events, and venous thromboembolic events as other Janus kinase inhibitors (jakinibs), results from phase 3 clinical trials suggest. Researchers examined data on treatment emergent adverse events among patients taking upadacitinib in five randomized…

Filed under:Drug Updates Tagged with:JAK inhibitorsjakinibRheumatoid Arthritis (RA)upadacitinib

RA Patients with ILD & Liver Disease Present Treatment Challenges

Vanessa Caceres  |  November 12, 2020

ACR CONVERGENCE 2020—Patients with concurrent rheumatological arthritis (RA) and liver disease or interstitial lung disease or treatment-refractory rheumatoid arthritis pose treatment challenges, according to the panelists of the ACR Convergence 2020’s How I Treat Difficult RA: Panel Session. Each panelist discussed a difficult case and raised questions on how to best treat it. Joan M….

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2020ACR Convergence 2020 – RA

Advantages of Embedding a Specialty Pharmacist in a Rheumatology Clinic

Polly J. Ferguson, MD, Jessica Lynton, PharmD, BCPS, & Beth H. Resman-Targoff, PharmD, FCCP, on behalf of the ARP Membership & Nominations Committee  |  November 12, 2020

The number of medications with rheumatologic indications has increased in parallel with expanding complexities of medication approval and delivery. Simply starting a patient on a biologic medication or new disease-modifying anti-rheumatic drug (DMARD) can be time consuming and frustrating for physicians, nurses and their support staff. In addition to educating the patient and obtaining prior…

Filed under:Drug UpdatesFrom the CollegePractice Support Tagged with:adherenceAssociation of Rheumatology Professionals (ARP)pharmacistprior authorization

  • « Previous Page
  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • 35
  • …
  • 107
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences